Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial‐to‐mesenchymal transition, inflammation and angiogenesis

Nintedanib, an Food and Drug Administration (FDA) approved multiple tyrosine kinase inhibitor, exhibits an anti‐fibrotic effect in lung and kidneys. Its effect on peritoneal fibrosis remains unexplored. In this study, we found that nintedanib administration lessened chlorhexidine gluconate (CG)‐indu...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Cell Mol Med
Hoofdauteurs: Liu, Feng, Yu, Chao, Qin, Huan, Zhang, Shenglei, Fang, Lu, Wang, Yi, Wang, Jun, Cui, Binbin, Hu, Susie, Liu, Na, Zhuang, Shougang
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2021
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256343/
https://ncbi.nlm.nih.gov/pubmed/33949772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.16518
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items